Clomiphene Citrate for Ovulation Induction and Male Hypogonadism
Ovulation Induction in Women
For women with polycystic ovary syndrome (PCOS) seeking pregnancy, clomiphene citrate is the first-line treatment for anovulatory infertility, with a standard starting dose of 50 mg daily for 5 days beginning on cycle day 5 1, 2, 3.
Dosing Protocol
- Initial dose: 50 mg daily for 5 days, starting on cycle day 5
- Dose escalation: If no ovulation occurs after the first cycle, increase to 100 mg daily for 5 days in subsequent cycles
- Maximum dose: Do not exceed 100 mg daily for 5 days 3
- Treatment duration: Limit to 6 ovulatory cycles total; if 3 ovulatory cycles occur without pregnancy, discontinue treatment 3
Monitoring Requirements
Ultrasound monitoring is mandatory for at least the first cycle to assess follicular development and minimize multiple pregnancy risk 4. The multiple pregnancy rate with clomiphene is approximately 3.6-12.5%, significantly lower than with gonadotropins 5.
Efficacy by Indication
PCOS patients: Approximately 80% achieve ovulation, with 50% of ovulating patients conceiving 1. Clomiphene produces lower live birth rates than gonadotropins but with substantially lower multiple pregnancy rates 5.
Functional hypothalamic amenorrhea (FHA): Clomiphene is not recommended as first-line therapy 6, 7. The 2017 Endocrine Society guideline suggests clomiphene only as a trial in FHA patients with sufficient endogenous estrogen levels, though most case series do not favor its use 6. Pulsatile GnRH (when available) or gonadotropins are preferred, as FHA patients typically cannot respond adequately to estrogen receptor blockade 6.
Critical Contraindications
- Pregnancy (must be excluded before each cycle)
- Ovarian cysts (except polycystic ovaries)
- Abnormal vaginal bleeding (evaluate for neoplasia first)
- Liver dysfunction
- BMI <18.5 kg/m² in FHA patients (increased risk of fetal loss, small-for-gestational-age babies, preterm labor) 6, 7
Common Pitfalls
Do not use clomiphene for unexplained infertility—the evidence is inconclusive 4. Ensure complete fertility workup including thyroid function, prolactin levels, tubal patency, and semen analysis before initiating treatment 3.
Male Hypogonadotropic Hypogonadism
Clomiphene citrate is NOT FDA-approved for male infertility, and the FDA label explicitly warns against this use due to reports of testicular tumors and gynecomastia 3. However, off-label use has become common practice for men with secondary hypogonadism who wish to preserve fertility.
Dosing for Men (Off-Label)
- Standard regimen: 25 mg every other day, titrated to 50 mg every other day based on testosterone response 8, 9
- Alternative high-dose regimen: 100 mg three times weekly (alternate days) 10
- Target testosterone: 550 ± 50 ng/dL 9
Efficacy in Men
Clomiphene increases testosterone levels comparably to testosterone gel (no significant difference in meta-analysis) but significantly less than injectable testosterone 11. In a large retrospective study of 2,518 matched patients, clomiphene achieved testosterone normalization while demonstrating significantly lower all-cause mortality (1.83% vs 10.13%) and fewer cardiovascular complications compared to testosterone replacement therapy 12.
Predictors of Response
Baseline luteinizing hormone (LH) is the strongest predictor of treatment failure—each 1 mIU/mL increase in baseline LH decreases response odds by 18% (OR 0.82) 13. Prior androgen deprivation therapy dramatically reduces response (OR 0.11) 13. Baseline testosterone level and age do not predict response 13.
Advantages Over Testosterone Replacement
- Preserves spermatogenesis and fertility 14, 9
- Avoids testicular atrophy 8
- Lower rates of polycythemia (1.07% vs 2.22%), hypertension (6.04% vs 10.48%), and cardiovascular events 12
- Physiologic testosterone increase via endogenous production 12, 11
Limitations
Clomiphene produces less improvement in libido compared to testosterone replacement (standardized mean difference -0.54) 11. Treatment response occurs in only 47% of patients within 12 weeks 13. Long-term safety beyond 19 months is not well-established 9.
When to Avoid Clomiphene in Men
- Elevated baseline LH (>5 mIU/mL suggests primary testicular failure) 13
- History of androgen deprivation therapy 13
- Severe hypogonadal symptoms requiring rapid testosterone normalization
- Patients prioritizing libido improvement over fertility preservation 11
Monitoring
Measure total testosterone, LH, FSH, and estradiol at baseline and every 3 months during treatment 8, 9. Adjust dose to maintain testosterone 400-600 ng/dL while avoiding supraphysiologic levels.